CD79A and COVID-19: The post-infection polyclonal IgM, IgA and IgG antibody-epitope repertoires were determined by GFPDL analysis conducted on polyclonal samples pooled from the first available time-point (within 1–4 days post-onset of symptoms) vs. plasma from the last time-point of either fatal COVID-19 patients (E-18, E-34, and E-58; Expired—<D4 & Expired—final sample) (shown in red in Fig. 3b, c, d), or non-ICU, surviving COVID-19 patients (NS-33 and NS-90; Survived—<D4 & Survived—Discharged) (shown in green in Fig. 3b, c, d).